By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
As I walked into a breakout session on Jan. 11, 2017, at the J.P. Morgan Healthcare Conference (JPM) in San Francisco, I couldn’t help but overhear a number of people discussing the latest negative news to hit the biopharmaceutical industry. In his first press conference as president-elect, Donald Trump slammed the biopharmaceutical industry for corporate inversions, overseas production, and yes — drug pricing too. And as is often the case during this annual event, the news spread like wildfire. Though the NASDAQ Biotechnology Index (NBI) declined 3 percent by day’s end, the tone of conference conversations remained confident, and in my opinion, rightfully so. Despite no biopharmaceutical executive wanting to end up on the wrong end of a Donald Trump tweet, there seems to be a strong sense of industry optimism. And why not, for we work in an industry focused on creating life-saving and life-improving therapies.